Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: A multicenter phase II study

Oncology

Volumn 70, Issue 4, 2006, Pages 280-284

  Androulakis, Nikolaos ^a   Aravantinos, Gerasimos ^b   Syrigos, Kostas ^c   Polyzos, Aris ^c   Ziras, Nikolaos ^e   Tselepatiotis, Evangelos ^d   Samonis, George ^a   Kentepozidis, Nikolaos ^a   Giassas, Stylianos ^a   Vamvakas, Lambros ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Agii Anargyri Anticancer Hospital of Athens   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d KAT HOSPITAL   (Greece)

^e General Anticancer METAXA Hospital   (Greece)

Author keywords

Biliary tract cancer; Oxaliplatin

Indexed keywords

CAPECITABINE; IRINOTECAN; OXALIPLATIN; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; METASTASIS; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33750570253     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096249     Document Type: Article

References (27)

1. Bartlett DL, Ramanathan RK, Deutsch M: Cancer of the biliary tree; in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 7. Philadelphia, Lippincott Williams and Wilkins, 2005, pp 1009-1035.
2. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
3. Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984;15:965-969.
4. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T: Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994;51:396-400.
5. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP: Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998;9:653-656.
6. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ: Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306-2310.
7. Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K, Sarra E, Souglakos J, Kakolyris S, Georgoulias V: First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract: a multicentre phase II study. Eur J Cancer 2001;37:1833-1838.
8. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, Ahumada M: A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001;12:1403-1406.
9. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12:183-186.
10. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML, Valdesi M: Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001;19:4089-4091.
11. Thongprasert S, Napapan S, Charoentum C, Moonprakan S: Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005;16:279-281.
12. Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ: Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of Princess Margaret Hospital experience. Ann Oncol 2004;15:770-774.
13. Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J, Yoshino M: A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994;51:515-517.
14. Taieb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M: Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002;13:1192-1196.
15. Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B; EORTC Gastro Intestinal Tract Cancer Group: A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005;41:398-403.
16. Doval DC, Sekhon JS, Fuloria J, Gupta SK, Vaid AK, Gupta S, Shukla VK: Gemcitabine and cisplatin in chemotherapy-naive, unresectable gallbladder cancer: a large multicenter, phase II study (abstract 622). Proc Soc Clin Oncol 2001;20:156a.
17. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD: Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 1998;4:1021-1029.
18. Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, Porschen R: Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002;87:702-704.
19. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C; GER-COR Group: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-1343.
20. Nehls O, Oettle H, Hartmann JT, Hofheinz R, Hochhaus A, Makowski M, Arnold D, Burkart C, Gregor M, Klump B: A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas (abstract 4091). Proc Soc Clin Oncol 2004;23:335.
21. Wagner AD, Buechner-Steudel P, Wein A, Moehler M, Schmalenberg H, Fahlke J, Kuss O, Behrens R, Kleber G, Fleig WE: Gemcitabine, oxaliplatin and weekly high-dose 5-FU as a 24-h-infusion in chemonaive patients with advanced or metastatic biliary tree adenocarcinoma: preliminary results of a multicenter phase II-study (abstract 4147). Proc Soc Clin Oncol 2005;23:344s.
22. National Cancer Institute: Guidelines for Reporting Adverse Drug Reactions. Bethesda, National Cancer Institute, 1978.
23. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, World Health Organization, 1979.
24. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
25. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
26. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-1695.
27. Malka D, Boige V, Dromain C, Debaere T, Pocard M, Ducreux M: Biliary tract neoplasms: update 2003. Curr Opin Oncol 2004; 16:364-371.